• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits.一种非离子表面活性剂囊泡制剂对兔体内阿昔洛韦口服生物利用度的影响。
AAPS PharmSciTech. 2007 Dec 14;8(4):E106. doi: 10.1208/pt0804106.
2
Development and evaluation of nanosized niosomal dispersion for oral delivery of Ganciclovir.纳米囊泡分散体制备及其用于更昔洛韦口服给药的研究与评价。
Drug Dev Ind Pharm. 2012 Jan;38(1):84-92. doi: 10.3109/03639045.2011.592529. Epub 2011 Jul 4.
3
Preparation and characterization of niosomes containing ribavirin for liver targeting.制备并表征含有利巴韦林的肝靶向尼奥斯omes。
Drug Deliv. 2010 Jul;17(5):282-7. doi: 10.3109/10717541003706257.
4
Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide.乙酰唑胺反相蒸发和多层非离子表面活性剂囊泡眼用载体的制备与评价
Int J Pharm. 2005 Dec 8;306(1-2):71-82. doi: 10.1016/j.ijpharm.2005.09.023. Epub 2005 Nov 2.
5
Enhanced oral bioavailability of griseofulvin via niosomes.通过非离子脂质体增强灰黄霉素的口服生物利用度。
AAPS PharmSciTech. 2009;10(4):1186-92. doi: 10.1208/s12249-009-9325-z. Epub 2009 Oct 24.
6
Effect of formulation compositions on niosomal preparations.制剂组成对非离子囊泡制剂的影响。
Pharm Dev Technol. 2013 May-Jun;18(3):667-72. doi: 10.3109/10837450.2012.672988. Epub 2012 Apr 2.
7
Nonpolymeric nanoassemblies for ocular administration of acyclovir: pharmacokinetic evaluation in rabbits.用于眼部给予阿昔洛韦的非聚合纳米组装体:在兔体内的药代动力学评价。
Eur J Pharm Biopharm. 2012 Jan;80(1):39-45. doi: 10.1016/j.ejpb.2011.10.001. Epub 2011 Oct 8.
8
Design and development of microemulsion drug delivery system of acyclovir for improvement of oral bioavailability.阿昔洛韦微乳给药系统的设计与开发以提高口服生物利用度。
AAPS PharmSciTech. 2006 Sep 15;7(3):77. doi: 10.1208/pt070377.
9
Design and development of multiple emulsion for enhancement of oral bioavailability of acyclovir.设计和开发复乳以提高阿昔洛韦的口服生物利用度。
Drug Dev Ind Pharm. 2013 Nov;39(11):1809-17. doi: 10.3109/03639045.2012.738682. Epub 2013 Jan 2.
10
In vitro Characterization and Release Studies of Combined Nonionic Surfactant-Based Vesicles for the Prolonged Delivery of an Immunosuppressant Model Drug.联合非离子表面活性剂囊泡的体外特性表征及释放研究用于延长免疫抑制剂模型药物的递送。
Int J Nanomedicine. 2020 Oct 14;15:7937-7949. doi: 10.2147/IJN.S268846. eCollection 2020.

引用本文的文献

1
In Vitro Oral Cavity Permeability Assessment to Enable Simulation of Drug Absorption.体外口腔通透性评估以实现药物吸收模拟
Pharmaceutics. 2025 Jul 17;17(7):924. doi: 10.3390/pharmaceutics17070924.
2
Nanoparticle tools for maximizing oral drug delivery.用于最大化口服药物递送的纳米颗粒工具。
Braz J Med Biol Res. 2025 Jun 16;58:e14459. doi: 10.1590/1414-431X2025e14459. eCollection 2025.
3
An industrial procedure for the intestinal permeability enhancement of acyclovir: in-vitro and histological evidence.一种用于增强阿昔洛韦肠道通透性的工业程序:体外和组织学证据。
Sci Rep. 2023 Nov 16;13(1):20067. doi: 10.1038/s41598-023-47306-2.
4
The characteristics and biological activity enhancements of melatonin encapsulations for skin care product applications.用于护肤品应用的褪黑素封装物的特性及生物活性增强
Int J Pharm X. 2023 Oct 29;6:100217. doi: 10.1016/j.ijpx.2023.100217. eCollection 2023 Dec 15.
5
A Comparative Study on Cyclodextrin Derivatives in Improving Oral Bioavailability of Etoricoxib as a Model Drug: Formulation and Evaluation of Solid Dispersion-Based Fast-Dissolving Tablets.以依托考昔为模型药物,比较环糊精衍生物对其口服生物利用度的改善作用:基于固体分散体的速溶片的制备与评价
Biomedicines. 2023 Sep 1;11(9):2440. doi: 10.3390/biomedicines11092440.
6
Novel nasal niosomes loaded with lacosamide and coated with chitosan: A possible pathway to target the brain to control partial-onset seizures.载有拉科酰胺并涂覆有壳聚糖的新型鼻腔脂质体:一种靶向大脑以控制部分性发作的可能途径。
Int J Pharm X. 2023 Aug 12;6:100206. doi: 10.1016/j.ijpx.2023.100206. eCollection 2023 Dec 15.
7
Niosomes: A Smart Drug Delivery System for Brain Targeting.脂质体:一种用于脑靶向的智能药物递送系统。
Pharm Nanotechnol. 2024;12(2):108-125. doi: 10.2174/2211738511666230524143832.
8
Advances in Antiviral Delivery Systems and Chitosan-Based Polymeric and Nanoparticulate Antivirals and Antiviral Carriers.抗病毒传递系统的进展及壳聚糖基聚合物和纳米颗粒抗病毒药物和抗病毒载体。
Viruses. 2023 Feb 28;15(3):647. doi: 10.3390/v15030647.
9
Strategies to improve the physicochemical properties of peptide-based drugs.提高基于肽的药物理化性质的策略。
Pharm Res. 2023 Mar;40(3):617-632. doi: 10.1007/s11095-023-03486-0. Epub 2023 Mar 3.
10
Formulation of novel niosomal repaglinide chewable tablets using coprocessed excipients: in vitro characterization, optimization and enhanced hypoglycemic activity in rats.采用共处理辅料制备新型瑞格列奈脂质体咀嚼片及其体外评价、优化和体内降血糖活性研究。
Drug Deliv. 2023 Dec;30(1):2181747. doi: 10.1080/10717544.2023.2181747.

本文引用的文献

1
Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir.口服伐昔洛韦后血清和脑脊液中的阿昔洛韦水平。
Antimicrob Agents Chemother. 2003 Aug;47(8):2438-41. doi: 10.1128/AAC.47.8.2438-2441.2003.
2
Preliminary pharmacokinetic study of different preparations of acyclovir with beta-cyclodextrin.阿昔洛韦与β-环糊精不同制剂的初步药代动力学研究。
J Pharm Sci. 2002 Dec;91(12):2593-8. doi: 10.1002/jps.10245.
3
Simple high-performance liquid chromatographic method for the determination of acyclovir in human plasma using fluorescence detection.采用荧光检测的高效液相色谱法测定人血浆中阿昔洛韦的简易方法。
J Chromatogr B Biomed Sci Appl. 1997 May 23;693(1):241-4. doi: 10.1016/s0378-4347(97)00041-8.
4
Management of herpes simplex and varicella-zoster virus infections.单纯疱疹和水痘-带状疱疹病毒感染的管理
West J Med. 1997 Mar;166(3):211-5.
5
Pharmacokinetics and bioavailability of different formulations of aciclovir.阿昔洛韦不同制剂的药代动力学和生物利用度。
Arzneimittelforschung. 1995 Apr;45(4):508-15.
6
A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability.生物药剂学药物分类的理论基础:体外药物溶出度与体内生物利用度的相关性。
Pharm Res. 1995 Mar;12(3):413-20. doi: 10.1023/a:1016212804288.
7
n-Alkyl-glucosides as detergents for the preparation of highly homogeneous bilayer liposomes of variable sizes ( 60-240 nm phi) applying defined rates of detergent removal by dialysis.正烷基葡糖苷作为去污剂,用于通过透析以规定的去污剂去除速率制备尺寸可变(直径60 - 240 nm)的高度均匀双层脂质体。
Biochem Biophys Res Commun. 1981 Jun 16;100(3):1055-62. doi: 10.1016/0006-291x(81)91930-6.
8
Species differences in the disposition of acyclovir.阿昔洛韦处置过程中的种属差异。
Am J Med. 1982 Jul 20;73(1A):31-5. doi: 10.1016/0002-9343(82)90059-6.
9
6-Deoxyacyclovir: a xanthine oxidase-activated prodrug of acyclovir.6-脱氧阿昔洛韦:阿昔洛韦的一种黄嘌呤氧化酶激活前药。
Proc Natl Acad Sci U S A. 1984 May;81(10):3209-13. doi: 10.1073/pnas.81.10.3209.
10
Pharmacokinetics of acyclovir after intravenous and oral administration.静脉注射和口服阿昔洛韦后的药代动力学
J Antimicrob Chemother. 1983 Sep;12 Suppl B:29-37. doi: 10.1093/jac/12.suppl_b.29.

一种非离子表面活性剂囊泡制剂对兔体内阿昔洛韦口服生物利用度的影响。

Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits.

作者信息

Attia Ismail A, El-Gizawy Sanaa A, Fouda Medhat A, Donia Ahmed M

机构信息

Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Tanta, Tanta, Egypt.

出版信息

AAPS PharmSciTech. 2007 Dec 14;8(4):E106. doi: 10.1208/pt0804106.

DOI:10.1208/pt0804106
PMID:18181527
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2750692/
Abstract

The purpose of this research was to prepare acyclovir niosomes in a trial to improve its poor and variable oral bioavailability. The nonionic surfactant vesicles were prepared by the conventional thin film hydration method. The lipid mixture consisted of cholesterol, span 60, and dicetyl phosphate in the molar ratio of 65:60:5, respectively. The percentage entrapment was approximately 11% of acyclovir used in the hydration process. The vesicles have an average size of 0.95 microm, a most probable size of 0.8 microm, and a size range of 0.4 to 2.2 microm. Most of the niosomes have unilamellar spherical shape. In vitro drug release profile was found to follow Higuchi's equation for free and niosomal drug. The niosomal formulation exhibited significantly retarded release compared with free drug. The in vivo study revealed that the niosomal dispersion significantly improved the oral bioavailability of acyclovir in rabbits after a single oral dose of 40 mg kg(-1). The average relative bioavailability of the drug from the niosomal dispersion in relation to the free solution was 2.55 indicating more than 2-fold increase in drug bioavailability. The niosomal dispersion showed significant increase in the mean residence time (MRT) of acyclovir reflecting sustained release characteristics. In conclusion, the niosomal formulation could be a promising delivery system for acyclovir with improved oral bioavailability and prolonged drug release profiles.

摘要

本研究的目的是制备阿昔洛韦脂质体,以改善其较差且不稳定的口服生物利用度。通过传统的薄膜水化法制备非离子表面活性剂囊泡。脂质混合物由胆固醇、司盘60和十六烷基磷酸酯组成,摩尔比分别为65:60:5。包封率约为水化过程中所用阿昔洛韦的11%。囊泡的平均大小为0.95微米,最可能大小为0.8微米,大小范围为0.4至2.2微米。大多数脂质体呈单层球形。体外药物释放曲线表明游离药物和脂质体药物均符合 Higuchi 方程。与游离药物相比,脂质体制剂的释放明显延迟。体内研究表明,单次口服剂量为40 mg kg(-1) 后,脂质体分散体显著提高了阿昔洛韦在兔体内的口服生物利用度。脂质体分散体中药物相对于游离溶液的平均相对生物利用度为2.55,表明药物生物利用度增加了两倍多。脂质体分散体显示阿昔洛韦的平均驻留时间 (MRT) 显著增加,反映了缓释特性。总之,脂质体制剂可能是一种有前景的阿昔洛韦给药系统,具有改善的口服生物利用度和延长的药物释放曲线。